Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01

Jan 3, 2023

News

Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01

Evaxion today announced that the U.S. Food and Drug Administration (“FDA”) determined that the Company may proceed with its Phase 2b clinical trial of EVX-01.

Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023

Dec 15, 2022

News

Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023

Evaxion today announced that they expect to present data from their two clinical trials of personalized cancer immunotherapies (cancer vaccines) EVX-01 and EVX-02 in the second quarter of 2023.

Evaxion and ExpreS<sup>2</sup>ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate

Dec 6, 2022

News

Evaxion and ExpreS2ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate

Evaxion has signed a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech for the joint development of a novel cytomegalovirus (CMV) vaccine candidate

Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02

Nov 17, 2022

News

Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02

Evaxion announced today promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02.

Evaxion Announces Third Quarter 2022 Financial Results and Business Update

Nov 14, 2022

News

Evaxion Announces Third Quarter 2022 Financial Results and Business Update

Evaxion announced today its third quarter 2022 financial results and provided an operational and business update

Evaxion CEO comments on strategic focus

Nov 10, 2022

News

Evaxion CEO comments on strategic focus

Evaxion today announced that it intends to further increase its focus on its lead oncology assets EVX-01 and EVX-02/03 to bring them to clinical proof of concept followed by out-licensing. The Company further plans preclinical partnering of its early-stage programs under its infectious disease platforms.

Evaxion welcomes Per Norlén as new CEO.

Oct 5, 2022

News

Evaxion welcomes Per Norlén as new CEO.

Evaxion announces that its new Chief Executive Officer (CEO) Per Norlén has joined the company on October 1st.

Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy

Sep 22, 2022

News

Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy

In the company’s first phase 2b clinical trial, Evaxion is evaluating the efficacy and safety of EVX-01 in adults with metastatic melanoma. The trial is being conducted globally at clinical sites across the US, Europe, and Australia in collaboration with Merck & Co., Inc., which is supplying the trial with its PD-1 inhibitor, KEYTRUDA®.

Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School

Sep 6, 2022

News

Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School

Evaxion announced that the Company, in collaboration with UMass Chan Medical School (“UMass Chan”), has received a grant from the U.S. National Institutes of Health (“NIH”) for the development of a gonorrhea lead vaccine candidate.